Advertisement
News
Advertisement

Zargis to Launch FDA-Cleared Lung Sounds Analysis Technology from Stethographics, Inc.

Sun, 06/13/2010 - 7:37pm
Bio-Medicine.Org

STAMFORD, Conn., June 11 /PRNewswire-FirstCall/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.  Zargis plans to incorporate the technology into its existing telemedicine and computer-aided auscultation platform in order to deliver these new diagnostic support tools to medical professionals.

Stethographics is a leading developer of automated, noninvasive sound analysis products designed to help medical professionals identify and interpret clinically significant lung sounds. The company was founded in 1998 by Dr. Raymond Murphy, a Professor of Medicine at Tufts University School of Medicine who also spent 25 years as an assistant professor at the Harvard School of Public Health.

The licensed technology allows lung sounds to be visually displayed in the form of traces, similar to the manner in which the Zargis Cardioscan heart murmur detection software displays stethoscope-captured heart sounds. The system also provides objective findings regarding clinically significant respiratory sounds such as wheezes, crackles and rhonchi. "We are excited to have partnered with Zargis Medical. Their award-winning platform has set a new standard for computer-aided sound analysis and tele-auscultation, and the inclusion of our technology in their systems should greatly aid healthcare profession

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading